3 Reasons Why Aphria’s (TSX:APH) Latest Acquisition Is a Really Big Deal

Aphria Inc (TSX:APH), ruffled a few feathers earlier this spring when it announced that it had closed on its $425 million deal to acquire Brampton, Ontario based medical marijuana company, Nuuvera. Find out why.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Canada’s third-largest marijuana company, Aphria Inc. (TSX:APH), ruffled a few feathers earlier this spring when it announced that it had closed on its $425 million deal to acquire Brampton, Ontario based medical marijuana company, Nuuvera.

Although Aphria ended up completing the purchase for $375 million less than the $800 million it had originally offered, the deal still had many analysts questioning why Aphria had been pursuing Nuuvera in the first place.

Thanks to a pretty severe sell-off in pot stocks to begin the year, Aphria was able to get better terms on the deal, but the lack of an established track record – both in terms of crop production and revenues – has the investing community scratching their heads.

But Aphria is a bit of a different beast compared to the rest of the pot producers that have seemingly flooded the Canadian stock exchanges since 2015, and there’s good reason to believe that the latest move could be Aphria management willing to take the long-view on how the market – particularly international markets, will end up shaking out.

The Nuuvera acquisition makes Aphria the world’s leading medical cannabis company

With the acquisition, Aphria will now be able to leverage Nuuvera’s expansive international partnerships, including supply and sales agreements that are in place in such lucrative medical cannabis markets as Germany, Italy, Spain, Malta, United Kingdom, Israel and Uruguay, among others.

Following the deal, Aphria now has a presence in 11 key markets, also including the United States and Australia.

In announcing the deal, Aphria’s CEO Vic Neufield said, “I would hope to show you that in one year we have 20 countries under license.”

With countries around the world trending towards more liberalized views on the drug – many of them being markets that are potentially much larger than what is currently being forecast for Canada – an aggressive international expansion strategy could be a key to Aphria’s success.

Aphria could soon have two GMP certified facilities in place

Along with the deal, Aphria signed two letters of intent to acquire GMP licensed facilities, one in Spain and one in Malta.

GMP stands for good manufacturing practices and is a key requirement of being able to sell pharmaceutical products into certain markets, including the European Union.

While it’s true that not all markets currently require GMP certification, based on the way the industry appears to be headed, it’s likely that at some point all facilities will need to be GMP certified. Thus, it’s great that Aphria is getting a head start in that regard, with the potential to share best practices with operations in other markets.

The deal should deliver complementary core competencies

Prior to the deal taking place, Aphria already held the leading edge as one of the lowest-cost cultivators in the market.

Thanks to the Nuuvera acquisition, Aphria will be able to leverage Nuuvera’s cannabis extraction, distillation, cannabinoid purification and formulation expertise.

In light of Aphria’s recent announcement to invest $55 million in a new state-of-the-art extraction facility near its Leamington, Ontario headquarters, it seems that in addition to going international, the company is also planning to make a big push into the extraction space.

Bottom line

There’s no question that it’s a very exciting time to be involved the marijuana industry, and the latest moves by Aphria demonstrate that the company is very willing to make a big splash in the market.

With shares down and valued at less than half of where they traded at the start of the year, now might be a good time to take a shot at this up-and-coming Canadian start-up.

Stay Foolish.

Just Released! 5 Stocks Under $50 (FREE REPORT)

Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $50 a share.

Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.

Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.

Claim your FREE 5-stock report now!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips owns shares in Aphria Inc.

If You Thought Apple and Microsoft Were Big, You Need to Read This.

The steel industry produced the world's first $1 billion company in 1901, and it wasn't until 117 years later that technology giant Apple became the first-ever company to reach a $1 trillion valuation.

But what if I told you artificial intelligence (AI) is about to accelerate the pace of value creation? AI has the potential to produce several trillion-dollar companies in the future, and The Motley Fool is watching one very closely right now.

Don't fumble this potential wealth-building opportunity by navigating it alone. The Motley Fool has a proven track record of picking revolutionary growth stocks early, from Netflix to Amazon, so become a premium member today.

See the 'AI Supercycle' Stock

More on Investing

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

The Absolute Best Canadian Stocks to Buy and Hold Forever in a TFSA

All three of these Canadian stocks have several advantages, making them some of the absolute best to buy and hold…

Read more »

Canadian dollars in a magnifying glass
Dividend Stocks

Take Full Advantage of Your TFSA With These Top Stocks for 2025

These TSX stocks offer attractive dividend yields.

Read more »

dividend growth for passive income
Investing

3 Canadian Growth Stars Under $30

These under-$30 TSX stock have promising long-term growth potential and will help investors accumulate significant wealth over time.

Read more »

jar with coins and plant
Dividend Stocks

3 Premium TSX Dividend Stars Trading Under $50

Reinvest the dividends of these three high-yielding stocks for superior returns.

Read more »

Women's fashion boutique Aritzia is a top stock to buy in September 2022.
Stocks for Beginners

Aritzia’s Latest Numbers: Is This Canadian Fashion Icon a Must-Buy?

Aritzia’s consistently strong financial performance clearly highlights its long-term growth potential.

Read more »

man touches brain to show a good idea
Investing

Value Investors: Here’s Where I’m Hunting in 2025

Spin Master (TSX:TOY) and another mid-cap value stock are worth watching this year.

Read more »

coins jump into piggy bank
Dividend Stocks

Dividend Seekers: Should You Buy Alaris Equity Stock for its 7.1% Yield?

Some dividend stocks just seem like one great deal, while others look too good to be true. So which is…

Read more »

Asset Management
Stocks for Beginners

2 TSX Champions Poised for Exceptional Long-Term Returns

These two TSX stocks with exceptional long-term growth potential offer great value right now.

Read more »